Federico De Marchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Federico De Marchi has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alessandra Sperotto
Veneto Institute of Oncology, Padua, Italy, Italy
6 shared publications - Michele Gottardi
Oncology-Veneto Institute of Oncology, Veneto Institute of Oncology, Padua, Italy, Italy
6 shared publications - Giulia Ciotti
UOSD Terapie Cellulari, Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padua, Italy
5 shared publications - Alessandro Atanasio
Istituto Oncologico Veneto, Padua, Italy, Italy
4 shared publications - Marco Basso
Oncology-Veneto Institute of Oncology, Veneto Institute of Oncology, Padua, Italy, Italy
4 shared publications - Roberta De Marchi
UOSD Terapie Cellulari, Dipartimento di Oncologia, Istituto Oncologico Veneto (IOV), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 35128 Padua, Italy
4 shared publications
Latest Publications
- Open Access
Maintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This narrative review, searched from Pubmed, from 2015 to 2026, critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, and treatment initiation and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
Open AccessMaintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This narrative review, searched from Pubmed, from 2015 to 2026, critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, and treatment initiation and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- Open Access
- 29 September 2026
- Published by MDPI AG in Preprints.org
Maintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This systematic review critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, treatment initiation, and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- 29 September 2026
- Published by MDPI AG in Preprints.org
Open AccessMaintenance Therapy After Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia: Still an Open Question?
Disease relapse remains the leading cause of treatment failure in patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic cell transplantation (allo-HCT). This systematic review critically synthesizes the available evidence on post-transplant maintenance strategies, which have evolved over the past three decades from conventional chemotherapy to molecularly targeted agents and interventions aimed at modulating antileukemic immunity. Particular attention is given to the biological rationale, efficacy, safety, and clinical applicability of these approaches, as well as to the substantial heterogeneity in study design, patient selection, treatment initiation, and duration. The available evidence indicates that the potential benefit of maintenance is unlikely to be uniform across all recipients and should be interpreted in relation to AML molecular features, baseline relapse risk, prior treatment exposure, measurable residual disease status, expected toxicity, and the patient’s overall clinical condition. Although selected strategies may prolong remission and improve survival, the optimal agent, timing, duration, and target population remain incompletely defined. Current evidence therefore supports a risk-adapted and molecularly informed approach, while underscoring the need for adequately powered prospective studies using standardized endpoints and incorporating quality-of-life outcomes.
- Open Access
Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep learning models read therapy-relevant mutations directly from bone marrow smears; automated flow cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor board support and trial matching. The next wave, from clonal architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict the scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier author-defined clinical readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
Open AccessPutting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep learning models read therapy-relevant mutations directly from bone marrow smears; automated flow cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor board support and trial matching. The next wave, from clonal architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict the scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier author-defined clinical readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- Open Access
- 5 August 2026
- Published by MDPI AG in Preprints.org
Putting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) produces more molecular, imaging, and clinical data per patient than any hematologist can hold in mind at once, and each revision of the WHO, ICC, and European LeukemiaNet (ELN) frameworks adds to the load. Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep-learning models read therapy-relevant mutations directly from bone-marrow smears; automated flow-cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug-response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor-board support and trial matching. The next wave, from clonal-architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier clinical-readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- 5 August 2026
- Published by MDPI AG in Preprints.org
Open AccessPutting the I in AML: Artificial Intelligence and Machine Learning in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) produces more molecular, imaging, and clinical data per patient than any hematologist can hold in mind at once, and each revision of the WHO, ICC, and European LeukemiaNet (ELN) frameworks adds to the load. Artificial intelligence (AI) and machine learning (ML) now reach into every stage of AML care. Deep-learning models read therapy-relevant mutations directly from bone-marrow smears; automated flow-cytometry gating reproduces expert calls in under a minute; and the first AI pathology devices for hematology have cleared regulatory review and entered clinical use. Beyond diagnosis, ML captures the age-dependent weight of individual mutations that categorical ELN scoring misses, drug-response prediction for venetoclax–azacitidine has been validated across multiple external cohorts, and large language models are being tested for tumor-board support and trial matching. The next wave, from clonal-architecture modeling and single-cell foundation models to digital twins and reinforcement learning for adaptive dosing, could move AML management from reactive toward predictive, evolution-aware care. This review departs from existing AI-in-hematology surveys in three ways: we (i) restrict scope to AML and organize the field around clinical decision points rather than technology categories, (ii) grade every tool on a five-tier clinical-readiness level (CRL-AML 1–5), which exposes hundreds of models clustered at CRL-AML 1–2 and none yet in prospective clinical evaluation, and (iii) close with a numbered three-year agenda naming the consortia, datasets, and pragmatic trials needed to carry the field from publication to practice.
- Open Access
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1679
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- 27 July 2026
- Published by MDPI AG in Biomedicines
- Vol. 14 (8) , 1679
Open AccessThe Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- Open Access
- 9 June 2026
- Published by MDPI AG in Preprints.org
The Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- 9 June 2026
- Published by MDPI AG in Preprints.org
Open AccessThe Role of the Bone Marrow Microenvironment in the Pathogenesis of Acute Myeloid Leukemia
Acute myeloid leukemia (AML) develops within a bone marrow environment that influences leukemic stem-cell behavior, residual disease, and response to therapy. This review examines evidence that the marrow microenvironment is not only a site of leukemic growth, but can actively shape AML initiation, maintenance, and treatment resistance. Clinical observations such as donor cell leukemia after allogeneic transplantation, together with experimental models in which stromal or osteolineage abnormalities induce myeloid disease, suggest that altered niches may contribute to leukemogenesis in selected settings. In established AML, vascular and endosteal compartments provide adhesive, chemokine, inflammatory, and metabolic signals that promote leukemic-cell retention, quiescence, survival, and chemotherapy tolerance. AML cells also remodel the surrounding marrow, suppressing normal hematopoiesis and generating stromal, endothelial, osteoblastic, adipocytic, and immune-cell programs that favor leukemic persistence. These interactions are especially relevant to drug resistance, including resistance to venetoclax-based therapy, where cytokine-mediated changes in apoptotic dependence, fatty-acid metabolism, mitochondrial adaptation, and stromal support may all contribute. Several therapeutic approaches have attempted to disrupt niche-mediated protection, including targeting CXCL12/CXCR4 signaling, adhesion pathways, inflammatory circuits, Hedgehog signaling, and metabolic dependencies. Although early-phase studies have shown activity in some AML subsets, randomized evidence remains limited and results have been inconsistent. We discuss how a better understanding of microenvironmental biology may help define when niche-directed therapy is most likely to complement conventional and molecularly targeted AML treatment.
- Open Access
- 22 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1837940
ACSL4-driven ferroptosis susceptibility as a targetable vulnerability in monocytic acute myeloid leukemia
Ferroptosis, an iron-dependent form of regulated cell death driven by lethal lipid peroxidation, has emerged as a targetable vulnerability in cancer. ACSL4 is the rate-limiting enzyme that dictates ferroptosis sensitivity by channeling polyunsaturated fatty acids into membrane phospholipids. In acute myeloid leukemia (AML), monocytic subtypes resist BCL2 inhibition with venetoclax, yet their metabolic dependencies remain poorly defined. Here, we integrated PRISM drug-sensitivity data (6,790 compounds) and DepMap CRISPR dependencies (18,435 genes) across 15 adult AML cell lines to map drug-gene co-dependencies. A multi-cohort validation strategy — filtering 50 discovery candidates (29 testable in BeatAML) through ex vivo drug-response data in 476 primary AML specimens and clinical outcomes in 140 adults with de novo AML (TCGA-LAML) — converged on a single axis linking SRC family kinase inhibition to ACSL4 expression. ACSL4 -high blasts showed enhanced dasatinib sensitivity ( r = -0.25, P = 4.3 x 10 -8 ). A composite SRC / ACSL4 signature stratified overall survival (HR 1.27; 95% CI 1.10-1.47; P = 0.0014), remaining significant after age adjustment. Single-cell atlas projection localized this signature to the monocytic compartment. The SRC / ACSL4 -high state displayed a ferroptosis gene expression profile characterized by co-upregulation of ACSL4 , HMOX1 , and LPCAT3 with failure to upregulate the principal ferroptosis defense axis GPX4 / SLC7A11 . Conversely, ACSL4 -high blasts showed significant ex vivo resistance to venetoclax ( r = 0.36, P = 2.5 x 10 -12 ), linking the ferroptosis-primed monocytic state to BCL2 inhibitor failure. These findings nominate ACSL4 -driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition.
- 22 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1837940
Open AccessACSL4-driven ferroptosis susceptibility as a targetable vulnerability in monocytic acute myeloid leukemia
Ferroptosis, an iron-dependent form of regulated cell death driven by lethal lipid peroxidation, has emerged as a targetable vulnerability in cancer. ACSL4 is the rate-limiting enzyme that dictates ferroptosis sensitivity by channeling polyunsaturated fatty acids into membrane phospholipids. In acute myeloid leukemia (AML), monocytic subtypes resist BCL2 inhibition with venetoclax, yet their metabolic dependencies remain poorly defined. Here, we integrated PRISM drug-sensitivity data (6,790 compounds) and DepMap CRISPR dependencies (18,435 genes) across 15 adult AML cell lines to map drug-gene co-dependencies. A multi-cohort validation strategy — filtering 50 discovery candidates (29 testable in BeatAML) through ex vivo drug-response data in 476 primary AML specimens and clinical outcomes in 140 adults with de novo AML (TCGA-LAML) — converged on a single axis linking SRC family kinase inhibition to ACSL4 expression. ACSL4 -high blasts showed enhanced dasatinib sensitivity ( r = -0.25, P = 4.3 x 10 -8 ). A composite SRC / ACSL4 signature stratified overall survival (HR 1.27; 95% CI 1.10-1.47; P = 0.0014), remaining significant after age adjustment. Single-cell atlas projection localized this signature to the monocytic compartment. The SRC / ACSL4 -high state displayed a ferroptosis gene expression profile characterized by co-upregulation of ACSL4 , HMOX1 , and LPCAT3 with failure to upregulate the principal ferroptosis defense axis GPX4 / SLC7A11 . Conversely, ACSL4 -high blasts showed significant ex vivo resistance to venetoclax ( r = 0.36, P = 2.5 x 10 -12 ), linking the ferroptosis-primed monocytic state to BCL2 inhibitor failure. These findings nominate ACSL4 -driven ferroptosis susceptibility as a lineage-specific vulnerability rendering monocytic AML selectively sensitive to SRC-directed therapy while resistant to BCL2 inhibition.